Miriplatin hydrate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 120200

CAS#: 250159-48-9 (hydrate)

Description: Miriplatin (MPT) is a novel platinum complex used in TACE that shows promise for the treatment of hepatocellular carcinoma (HCC). Miriplatin is a lipophilic platinum complex that can be easily suspended in Lipiodol and gradually releases active platinum compounds in tumor tissue. Miriplatin is less severe toxicity profile compared to other platinum anticancer agents.


Chemical Structure

img
Miriplatin hydrate
CAS# 250159-48-9 (hydrate)

Theoretical Analysis

MedKoo Cat#: 120200
Name: Miriplatin hydrate
CAS#: 250159-48-9 (hydrate)
Chemical Formula: C34H68N2O4Pt
Exact Mass:
Molecular Weight: 764.0
Elemental Analysis: C, 52.22; H, 9.02; N, 3.58; O, 10.23; Pt, 24.95

Size Price Shipping out time Quantity
10mg USD 150 Same day
25mg USD 250 Same day
50mg USD 450 Same day
100mg USD 650 Same day
200mg USD 850 Same day
500mg USD 1250 Same day
1g USD 1950 Same day
2g USD 2950 Same day
5g USD 4950 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-03-02. Prices are subject to change without notice.

Miriplatin hydrate, purity > 98%, is in stock. The same day shipping out after order is received.

Related CAS #: 250159-48-9 (hydrate)   141977-79-9    

Synonym: SM 11355; SM-11355; SM11355; Miripla; Miriplatin; Miriplatin hydrate; MTP.

IUPAC/Chemical Name: (1R,2R)-cyclohexane-1,2-diamine;platinum(2+);tetradecanoate;hydrate

InChi Key: LWDBMUAJGMXQAY-GSEQGPDBSA-L

InChi Code: InChI=1S/2C14H28O2.C6H14N2.H2O.Pt/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16;7-5-3-1-2-4-6(5)8;;/h2*2-13H2,1H3,(H,15,16);5-6H,1-4,7-8H2;1H2;/q;;;;+2/p-2/t;;5-,6-;;/m..1../s1

SMILES Code: O=C(O[Pt-2]1(OC(CCCCCCCCCCCCC)=O)[NH2+][C@H]2[C@@H](CCCC2)[NH2+]1)CCCCCCCCCCCCC.[H]O[H]

Appearance:
White solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
Soluble in DMSO, not in water 100.0

Preparing Stock Solutions

The following data is based on the product molecular weight 764.0 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Yasui D, Murata S, Onozawa S, Mine T, Ueda T, Sugihara F, Kawamoto C, Uchida E, Kumita S. Improved efficacy of transcatheter arterial chemoembolization using warmed miriplatin for hepatocellular carcinoma. Biomed Res Int. 2014;2014:359296. doi: 10.1155/2014/359296. Epub 2014 Sep 8. PubMed PMID: 25276780; PubMed Central PMCID: PMC4172877.

2: Arai H, Abe T, Takayama H, Toyoda M, Ueno T, Kakizaki S, Sato K. Safety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma. Hepatol Res. 2014 Aug 8. doi: 10.1111/hepr.12403. [Epub ahead of print] PubMed PMID: 25132539.

3: Ishikawa T, Abe S, Inoue R, Sugano T, Watanabe Y, Iwanaga A, Seki K, Honma T, Nemoto T, Takeda K, Yoshida T. Predictive factor of local recurrence after balloon-occluded TACE with miriplatin (MPT) in hepatocellular carcinoma. PLoS One. 2014 Jul 21;9(7):e103009. doi: 10.1371/journal.pone.0103009. eCollection 2014. PubMed PMID: 25047920; PubMed Central PMCID: PMC4105420.

4: Ito T, Okubo H, Kokubu S, Miyazaki A, Ando H, Fujimura A, Watanabe S. Radiofrequency ablation combined with chemolipiodolization in a porcine liver: Comparison of the pharmacokinetic analysis with cisplatin powder and miriplatin. Hepatol Res. 2014 Jul 7. doi: 10.1111/hepr.12387. [Epub ahead of print] PubMed PMID: 25040841.

5: Otsuji K, Takai K, Nishigaki Y, Shimizu S, Hayashi H, Imai K, Suzuki Y, Hanai T, Ideta T, Miyazaki T, Tomita E, Shimizu M, Moriwaki H. Efficacy and safety of cisplatin versus miriplatin in transcatheter arterial chemoembolization and transarterial infusion chemotherapy for hepatocellular carcinoma: A randomized controlled trial. Hepatol Res. 2014 Jun 24. doi: 10.1111/hepr.12376. [Epub ahead of print] PubMed PMID: 24961745.

6: Okimoto K, Ogasawara S, Chiba T, Ooka Y, Oobu M, Azemoto R, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Yoshikawa M, Yokosuka O. Efficacy of transcatheter arterial chemoembolization with miriplatin-lipiodol water-soluble contrast agent emulsion in patients with hepatocellular carcinoma. Anticancer Res. 2013 Dec;33(12):5603-9. PubMed PMID: 24324105.

7: Yamanaka T, Takaki H, Nakatsuka A, Uchida K, Junji U, Fujimori M, Hasegawa T, Yoneda M, Shiraishi T, Sakuma H, Yamakado K. Radiofrequency ablation after arterial injection of miriplatin-iodized oil suspension into swine liver: ablative zone size and tissue platinum concentration. Cardiovasc Intervent Radiol. 2014 Aug;37(4):1047-52. doi: 10.1007/s00270-013-0779-8. PubMed PMID: 24232037.

8: Hashimoto N, Iwazawa J, Ohue S, Mitani T. Effect of transarterial chemoembolization with miriplatin plus epirubicin on local control of hepatocellular carcinoma: a retrospective comparison with miriplatin monotherapy. Onco Targets Ther. 2013 Aug 1;6:1025-30. doi: 10.2147/OTT.S49443. eCollection 2013. PubMed PMID: 23986641; PubMed Central PMCID: PMC3753878.

9: Handa T, Imai Y, Sugawara K, Chikayama T, Nakazawa M, Ando S, Hamaoka K, Inao M, Nakayama N, Mochida S. Transcatheter arterial chemoembolization for hepatocellular carcinoma: Comparison of the therapeutic efficacies between miriplatin and epirubicin. Hepatol Res. 2013 Aug 19. doi: 10.1111/hepr.12225. [Epub ahead of print] PubMed PMID: 23957866.

10: Ueda T, Murata S, Yasui D, Mine T, Kumita S. Comparison of the antitumor efficacy of transcatheter arterial chemoembolization with a miriplatin-iodized oil suspension and a cisplatin-iodized oil suspension for hepatocellular carcinoma. Hepatol Res. 2013 Oct;43(10):1071-7. doi: 10.1111/hepr.12212. Epub 2013 Aug 19. PubMed PMID: 23905645.



Additional Information